Intellia Therapeutics (NASDAQ:NTLA) Receives Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Intellia Therapeutics (NASDAQ:NTLA) in a research report sent to investors on Tuesday,Benzinga reports. The brokerage currently has a $30.00 price target on the stock.

Several other analysts also recently issued reports on NTLA. Wedbush reissued a “neutral” rating and set a $10.00 target price on shares of Intellia Therapeutics in a research note on Monday. Wells Fargo & Company lowered their target price on shares of Intellia Therapeutics from $60.00 to $50.00 and set an “overweight” rating on the stock in a report on Friday, February 28th. StockNews.com upgraded shares of Intellia Therapeutics to a “sell” rating in a research report on Monday, March 3rd. Truist Financial reduced their price target on shares of Intellia Therapeutics from $90.00 to $50.00 and set a “buy” rating on the stock in a report on Tuesday, March 4th. Finally, The Goldman Sachs Group reissued a “sell” rating and set a $9.00 price objective on shares of Intellia Therapeutics in a report on Friday, February 28th. Two analysts have rated the stock with a sell rating, six have issued a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $36.90.

Intellia Therapeutics Price Performance

NTLA opened at $9.67 on Tuesday. The company has a 50 day simple moving average of $7.98 and a two-hundred day simple moving average of $10.68. The firm has a market cap of $1.00 billion, a P/E ratio of -1.78 and a beta of 2.33. Intellia Therapeutics has a 1-year low of $5.90 and a 1-year high of $28.18.

Intellia Therapeutics (NASDAQ:NTLA) last issued its earnings results on Thursday, May 8th. The company reported ($1.10) earnings per share for the quarter, topping the consensus estimate of ($1.26) by $0.16. The firm had revenue of $16.63 million during the quarter, compared to the consensus estimate of $11.39 million. During the same period in the prior year, the company posted ($1.12) EPS. The company’s quarterly revenue was down 42.6% on a year-over-year basis. Equities analysts anticipate that Intellia Therapeutics will post -5.07 earnings per share for the current year.

Institutional Trading of Intellia Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. Regeneron Pharmaceuticals Inc. purchased a new stake in shares of Intellia Therapeutics in the fourth quarter valued at $43,177,000. Voloridge Investment Management LLC grew its holdings in Intellia Therapeutics by 226.8% during the 4th quarter. Voloridge Investment Management LLC now owns 1,526,994 shares of the company’s stock valued at $17,805,000 after purchasing an additional 1,059,751 shares during the last quarter. Contrarius Group Holdings Ltd purchased a new stake in Intellia Therapeutics in the 4th quarter worth about $11,798,000. Two Sigma Advisers LP lifted its stake in Intellia Therapeutics by 94.5% in the fourth quarter. Two Sigma Advisers LP now owns 1,998,317 shares of the company’s stock worth $23,300,000 after purchasing an additional 970,700 shares during the last quarter. Finally, Two Sigma Investments LP lifted its stake in Intellia Therapeutics by 88.1% in the fourth quarter. Two Sigma Investments LP now owns 1,843,743 shares of the company’s stock worth $21,498,000 after purchasing an additional 863,363 shares during the last quarter. 88.77% of the stock is currently owned by institutional investors.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.